Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia

Successful intensive induction chemotherapy for acute myeloid leukemia (AML) results in at least a 2 to 4 log10 reduction in the 1 trillion malignant cells that are present at diagnosis, often with recovery of normal platelet and neutrophil levels within a month after treatment initiation — an impressive result for a short course of treatment. More than half of patients with AML achieve remission after intensive induction therapy with an anthracycline and cytarabine, but relapse is common. Predicting the likelihood of relapse for an individual patient can be helpful in tailoring the intensity of postremission treatment.1 Even when a patient . . .